University of Notre Dame DU Lac lessened its holdings in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 7.1% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 37,926 shares of the biopharmaceutical company’s stock after selling 2,906 shares during the quarter. Alexion Pharmaceuticals makes up approximately 1.5% of University of Notre Dame DU Lac’s investment portfolio, making the stock its 18th largest position. University of Notre Dame DU Lac’s holdings in Alexion Pharmaceuticals were worth $5,321,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. BlackRock Inc. raised its holdings in Alexion Pharmaceuticals by 7.0% during the 2nd quarter. BlackRock Inc. now owns 19,926,265 shares of the biopharmaceutical company’s stock worth $2,424,428,000 after purchasing an additional 1,298,185 shares during the last quarter. Vanguard Group Inc. raised its holdings in Alexion Pharmaceuticals by 2.2% during the 2nd quarter. Vanguard Group Inc. now owns 14,785,831 shares of the biopharmaceutical company’s stock worth $1,798,992,000 after purchasing an additional 318,375 shares during the last quarter. State Street Corp raised its holdings in Alexion Pharmaceuticals by 5.0% during the 2nd quarter. State Street Corp now owns 11,860,647 shares of the biopharmaceutical company’s stock worth $1,443,099,000 after purchasing an additional 561,962 shares during the last quarter. Ameriprise Financial Inc. raised its holdings in Alexion Pharmaceuticals by 3.5% during the 3rd quarter. Ameriprise Financial Inc. now owns 6,390,301 shares of the biopharmaceutical company’s stock worth $896,491,000 after purchasing an additional 215,005 shares during the last quarter. Finally, Jennison Associates LLC raised its holdings in Alexion Pharmaceuticals by 720.0% during the 3rd quarter. Jennison Associates LLC now owns 5,332,636 shares of the biopharmaceutical company’s stock worth $748,116,000 after purchasing an additional 4,682,336 shares during the last quarter. Institutional investors and hedge funds own 94.16% of the company’s stock.

Shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) opened at $111.75 on Tuesday. The firm has a market cap of $24,970.00, a price-to-earnings ratio of 22.28, a PEG ratio of 1.19 and a beta of 1.18. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.96 and a quick ratio of 2.51. Alexion Pharmaceuticals, Inc. has a one year low of $96.18 and a one year high of $149.34.

Alexion Pharmaceuticals (NASDAQ:ALXN) last released its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $1.44 earnings per share for the quarter, beating the consensus estimate of $1.32 by $0.12. Alexion Pharmaceuticals had a net margin of 14.57% and a return on equity of 12.55%. The company had revenue of $859.00 million during the quarter, compared to analyst estimates of $864.34 million. During the same quarter in the previous year, the business posted $1.23 EPS. Alexion Pharmaceuticals’s revenue for the quarter was up 7.5% compared to the same quarter last year. analysts expect that Alexion Pharmaceuticals, Inc. will post 4.82 earnings per share for the current fiscal year.

Several research firms have issued reports on ALXN. Royal Bank Of Canada began coverage on shares of Alexion Pharmaceuticals in a report on Thursday, September 14th. They set an “outperform” rating and a $161.00 price target for the company. J P Morgan Chase & Co upgraded shares of Alexion Pharmaceuticals from a “neutral” rating to an “overweight” rating and raised their price target for the stock from $163.00 to $175.00 in a report on Tuesday, September 5th. Deutsche Bank restated a “buy” rating and set a $158.00 price target (up previously from $153.00) on shares of Alexion Pharmaceuticals in a report on Wednesday, September 13th. Leerink Swann restated an “outperform” rating and set a $182.00 price target (up previously from $170.00) on shares of Alexion Pharmaceuticals in a report on Wednesday, September 13th. They noted that the move was a valuation call. Finally, SunTrust Banks restated a “buy” rating and set a $180.00 price target (up previously from $170.00) on shares of Alexion Pharmaceuticals in a report on Wednesday, September 13th. Five analysts have rated the stock with a hold rating, eighteen have given a buy rating and two have assigned a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $155.06.

TRADEMARK VIOLATION WARNING: This story was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of US & international trademark & copyright laws. The legal version of this story can be viewed at https://www.thecerbatgem.com/2017/12/05/university-of-notre-dame-du-lac-reduces-position-in-alexion-pharmaceuticals-inc-alxn.html.

Alexion Pharmaceuticals Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Stock Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.